These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 10499598)
1. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. Pai-Scherf LH; Villa J; Pearson D; Watson T; Liu E; Willingham MC; Pastan I Clin Cancer Res; 1999 Sep; 5(9):2311-5. PubMed ID: 10499598 [TBL] [Abstract][Full Text] [Related]
2. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. Reiter Y; Brinkmann U; Jung SH; Lee B; Kasprzyk PG; King CR; Pastan I J Biol Chem; 1994 Jul; 269(28):18327-31. PubMed ID: 7913461 [TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of intraperitoneal Pseudomonas exotoxin immunoconjugate OVB3-PE in patients with ovarian cancer. Pai LH; Bookman MA; Ozols RF; Young RC; Smith JW; Longo DL; Gould B; Frankel A; McClay EF; Howell S J Clin Oncol; 1991 Dec; 9(12):2095-103. PubMed ID: 1960550 [TBL] [Abstract][Full Text] [Related]
4. Characterization of B1(Fv)PE38 and B1(dsFv)PE38: single-chain and disulfide-stabilized Fv immunotoxins with increased activity that cause complete remissions of established human carcinoma xenografts in nude mice. Benhar I; Pastan I Clin Cancer Res; 1995 Sep; 1(9):1023-9. PubMed ID: 9816075 [TBL] [Abstract][Full Text] [Related]
5. Recombinant immunotoxins. Pastan I; Pai LH; Brinkmann U; FitzGerald D Breast Cancer Res Treat; 1996; 38(1):3-9. PubMed ID: 8825117 [TBL] [Abstract][Full Text] [Related]
6. A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Weldon JE; Xiang L; Chertov O; Margulies I; Kreitman RJ; FitzGerald DJ; Pastan I Blood; 2009 Apr; 113(16):3792-800. PubMed ID: 18988862 [TBL] [Abstract][Full Text] [Related]
8. Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo. Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W Int J Cancer; 2000 Apr; 86(2):269-75. PubMed ID: 10738256 [TBL] [Abstract][Full Text] [Related]
9. Lowering the isoelectric point of the Fv portion of recombinant immunotoxins leads to decreased nonspecific animal toxicity without affecting antitumor activity. Onda M; Nagata S; Tsutsumi Y; Vincent JJ; Wang Q; Kreitman RJ; Lee B; Pastan I Cancer Res; 2001 Jul; 61(13):5070-7. PubMed ID: 11431343 [TBL] [Abstract][Full Text] [Related]
10. Phase 1 study of the anti-CD22 immunotoxin moxetumomab pasudotox for childhood acute lymphoblastic leukemia. Wayne AS; Shah NN; Bhojwani D; Silverman LB; Whitlock JA; Stetler-Stevenson M; Sun W; Liang M; Yang J; Kreitman RJ; Lanasa MC; Pastan I Blood; 2017 Oct; 130(14):1620-1627. PubMed ID: 28983018 [TBL] [Abstract][Full Text] [Related]
11. New immunotoxins targeting CD123, a stem cell antigen on acute myeloid leukemia cells. Du X; Ho M; Pastan I J Immunother; 2007 Sep; 30(6):607-13. PubMed ID: 17667524 [TBL] [Abstract][Full Text] [Related]
12. Recombinant single-chain and disulfide-stabilized Fv-immunotoxins that cause complete regression of a human colon cancer xenograft in nude mice. Reiter Y; Wright AF; Tonge DW; Pastan I Int J Cancer; 1996 Jul; 67(1):113-23. PubMed ID: 8690511 [TBL] [Abstract][Full Text] [Related]
13. A bivalent disulfide-stabilized Fv with improved antigen binding to erbB2. Bera TK; Onda M; Brinkmann U; Pastan I J Mol Biol; 1998 Aug; 281(3):475-83. PubMed ID: 9698563 [TBL] [Abstract][Full Text] [Related]
14. Anti-tumor activities of immunotoxins made of monoclonal antibody B3 and various forms of Pseudomonas exotoxin. Pai LH; Batra JK; FitzGerald DJ; Willingham MC; Pastan I Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3358-62. PubMed ID: 2014255 [TBL] [Abstract][Full Text] [Related]
15. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma. Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168 [TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo cytotoxic activities of recombinant immunotoxin 8H9(Fv)-PE38 against breast cancer, osteosarcoma, and neuroblastoma. Onda M; Wang QC; Guo HF; Cheung NK; Pastan I Cancer Res; 2004 Feb; 64(4):1419-24. PubMed ID: 14973056 [TBL] [Abstract][Full Text] [Related]
17. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Kreitman RJ; Pastan I Cancer Res; 1998 Mar; 58(5):968-75. PubMed ID: 9500458 [TBL] [Abstract][Full Text] [Related]
18. Recombinant immunotoxin containing a disulfide-stabilized Fv directed at erbB2 that does not require proteolytic activation. Kuan CT; Pastan I Biochemistry; 1996 Mar; 35(9):2872-7. PubMed ID: 8608123 [TBL] [Abstract][Full Text] [Related]
19. The performance of e23(Fv)PEs, recombinant toxins targeting the erbB-2 protein. King CR; Fischer PH; Rando RF; Pastan I Semin Cancer Biol; 1996 Apr; 7(2):79-86. PubMed ID: 8740563 [TBL] [Abstract][Full Text] [Related]
20. Immunotoxins in the treatment of refractory hairy cell leukemia. Kreitman RJ; Pastan I Hematol Oncol Clin North Am; 2006 Oct; 20(5):1137-51, viii. PubMed ID: 16990113 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]